Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed FCF Margin for 3 consecutive years, with 2305.69% as the latest value for Q2 2025.

  • Quarterly FCF Margin rose 5495231.0% to 2305.69% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 9346.65% through Dec 2025, up 686234.0% year-over-year, with the annual reading at 9986.54% for FY2025, 8851646.0% up from the prior year.
  • FCF Margin for Q2 2025 was 2305.69% at Inhibrx Biosciences, down from 1334.88% in the prior quarter.
  • The five-year high for FCF Margin was 1334.88% in Q1 2025, with the low at 57258.0% in Q2 2024.
  • Average FCF Margin over 3 years is 21591.3%, with a median of 3688.07% recorded in 2023.
  • The sharpest move saw FCF Margin plummeted -4004793bps in 2024, then surged 5495231bps in 2025.
  • Over 3 years, FCF Margin stood at 3688.07% in 2023, then plummeted by -1086bps to 43736.0% in 2024, then soared by 95bps to 2305.69% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 2305.69%, 1334.88%, and 43736.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.